Pluri Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Pluri Inc. (PLUR) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $165.00 thousand for the 9-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-05-14
- Pluri Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $121.00K, a 87.68% decline year-over-year.
- Pluri Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was -$4.00K, a 128.57% decline year-over-year.
- Pluri Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $48.00K, a 166.67% increase year-over-year.
- Pluri Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $982.00K, a 24450.00% increase year-over-year.
- Pluri Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $82.00K, a 36.67% increase from fiscal 2023.
- Pluri Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $60.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-03-31 | $121.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-14 | $117.00K derived: sum of 2 quarters · filed 2026-05-14 | $165.00K 10-Q · filed 2026-05-14 | |
| 2025-12-31 | -$4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | $44.00K 10-Q · filed 2026-02-12 | ||
| 2025-09-30 | $48.00K 10-Q · filed 2025-11-12 | |||
| 2025-03-31 | $982.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-14 | $996.00K derived: sum of 2 quarters · filed 2026-05-14 | $1.01M 10-Q · filed 2026-05-14 | $1.01M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | $32.00K 10-Q · filed 2026-02-12 | $32.00K derived: sum of 3 quarters · filed 2026-02-12 | $36.00K derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-09-30 | $18.00K 10-Q · filed 2025-11-12 | $18.00K derived: sum of 2 quarters · filed 2025-11-12 | $22.00K derived: sum of 3 quarters · filed 2025-11-12 | $75.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-18 | $4.00K derived: sum of 2 quarters · filed 2024-09-18 | $57.00K derived: sum of 3 quarters · filed 2025-02-11 | $82.00K 10-K · filed 2024-09-18 |
| 2024-03-31 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-09 | $57.00K derived: sum of 2 quarters · filed 2025-02-11 | $82.00K 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $53.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-11 | $78.00K 10-Q · filed 2025-02-11 | ||
| 2023-09-30 | $25.00K 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | $60.00K 10-K · filed 2024-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |